` 4503 (Astellas Pharma Inc) vs Nikkei 225 Comparison - Alpha Spread

4503
vs
Nikkei 225

Over the past 12 months, has outperformed Nikkei 225, delivering a return of -6% compared to the Nikkei 225's 7% drop.

Stocks Performance
4503 vs Nikkei 225

Loading

Performance Gap
4503 vs Nikkei 225

Loading
4503
Nikkei 225
Difference

Performance By Year
4503 vs Nikkei 225

Loading
4503
Nikkei 225
Add Stock

Competitors Performance
Astellas Pharma Inc vs Peers

Nikkei 225
4503
LLY
JNJ
NOVO B
ROG
Add Stock

Astellas Pharma Inc
Glance View

Economic Moat
None
Market Cap
2.4T JPY
Industry
Pharmaceuticals

Astellas Pharma Inc., a beacon in Japan's pharmaceutical landscape, weaves its narrative from a rich tapestry of innovation and strategic acumen. Born from the 2005 merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd., Astellas quickly established itself as a global powerhouse based in Tokyo. The company operates primarily by investing heavily in R&D to drive breakthroughs in life sciences, particularly focusing on therapeutic areas like oncology, urology, immunology, and transplant-related therapies. Through these focal points, Astellas channels its resources to cultivate novel treatments that address unmet medical needs, thereby enhancing the quality of life for patients worldwide. The financial architecture of Astellas Pharma is underpinned by its strategic prowess in expanding its product pipelines and leveraging partnerships to amplify its reach. Revenue generation primarily hinges on its robust product offerings, spearheaded by successful medications such as XTANDI for prostate cancer and Prograf, which aids in organ transplantation outcomes. This diversified product portfolio is complemented by an astute approach to global market penetration, where Astellas not only markets these pharmaceuticals but also strategically collaborates with biotech firms and research institutions to harness cutting-edge technologies. This business model not only propels profitability but also ensures that Astellas remains at the forefront of medical innovation, positioning itself as a pivotal entity within the pharmaceutical industry.

Intrinsic Value
1 864.62 JPY
Undervaluation 27%
Intrinsic Value
Price
Back to Top